Literature DB >> 6181407

Lack of expression of HLA-ABC antigens in choriocarcinoma and other human tumor cell lines.

P J Travers, J L Arklie, J Trowsdale, R A Patillo, W F Bodmer.   

Abstract

We studied a panel of 21 human tumor and other cell lines, mainly of epithelial origin, for the expression of HLA-ABC antigens by an indirect radiobinding assay using monoclonal antibodies. Four of the lines, 2 choriocarcinomas, a breast tumor cell lin (MDA-MB-157), and a colon carcinoma (LoVo) showed no detectable reaction with the antibodies. The levels of binding in another breast tumor line (SkBr3) and a colon carcinoma line (LS174T) were much reduced. These cell lines plus some of the HLA-ABC positive lines from the panel were studied by immunoprecipitation of 35S-labeled cell extracts. Two mechanisms for alteration of the HLA-ABC antigen levels at the cell surface were apparent. In the choriocarcinomas and one breast tumor line, beta 2 microglobulin (beta 2m) was expressed but little or no HLA-A, B, or C polypeptides were synthesized. The other HLA-ABC negative lines had defects similar to that in the previously reported Burkitt's lymphoma cell line DAUDI. In these lines, HLA-ABC polypeptides were produced but did not appear at the cell surface because beta 2m was not synthesized. The absence of HLA-ABC determinants from the cell surface is presumed to afford protection against T-cell immune attack whether naturally as against the trophoblast during pregnancy or in abnormal situations against certain tumors.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6181407

Source DB:  PubMed          Journal:  Natl Cancer Inst Monogr        ISSN: 0083-1921


  13 in total

1.  A transcription factor interacting with the class I gene enhancer is inactive in tumorigenic cell lines which suppress major histocompatibility complex class I genes.

Authors:  U Henseling; W Schmidt; H R Schöler; P Gruss; A K Hatzopoulos
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

2.  Negative and positive regulation of human leukocyte antigen class I gene transcription in K562 leukemia cells.

Authors:  E Chen; R W Karr; G D Ginder
Journal:  Mol Cell Biol       Date:  1987-12       Impact factor: 4.272

Review 3.  The HLA system: structure and function.

Authors:  W F Bodmer
Journal:  J Clin Pathol       Date:  1987-09       Impact factor: 3.411

Review 4.  Experimental strategies for modification of histocompatibility antigens in tumor cells.

Authors:  J Vogel; K Tanaka; G S Hoekzema; G Jay
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

5.  Loss of HLA-A,B,C allele products and lymphocyte function-associated antigen 3 in colorectal neoplasia.

Authors:  M E Smith; S G Marsh; J G Bodmer; K Gelsthorpe; W F Bodmer
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

6.  Differential diagnostic significance of the paucity of HLA-I antigens on metastatic breast carcinoma cells in effusions.

Authors:  E Magyarosy; W J Martin; E W Chu; S E Martin
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

7.  Control of synthesis and expression of H-2 heavy chain and beta-2 microglobulin in AKR leukemias.

Authors:  W Schmidt; U Henseling; D Bevec; A D Alonzo; H Festenstein
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

8.  Induction of cell-mediated immunity against B16-BL6 melanoma in mice vaccinated with cells modified by hydrostatic pressure and chemical crosslinking.

Authors:  A Eisenthal; V Ramakrishna; Y Skornick; M Shinitzky
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

9.  Expression of major histocompatibility complex class I antigens as a strategy for the potentiation of immune recognition of tumor cells.

Authors:  K Tanaka; H Hayashi; C Hamada; G Khoury; G Jay
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

10.  A novel downstream regulatory element of the mouse H-2Kb class I major histocompatibility gene.

Authors:  J Králová; P Jansa; J Forejt
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.